Seres Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Here Are 5 ‘Strong Buy’ Stocks For Under $10
Article By: TipRanks
Sunday, November 26, 2017 10:00 AM EST
Cheap stocks can be a smart choice for investors, as there are serious bargains to be found. The stocks below may be cheap, but they all have significant support from Wall Street’s best-performing analysts.
In this article: CVU, AMRN, MCRB, CDNA, MRAM
Read
3 Market-Beating Stocks For Your 2018 Radar (With Extreme Upside Potential)
Article By: TipRanks
Monday, October 16, 2017 8:47 AM EST
This little-known biotech stock has only received three buy ratings from top analysts in the last three months. However, these three analysts are all confident on one thing: that Gemphire has serious upside potential.
In this article: MCRB, LITE, GEMP
Read
E Seres Therapeutics Tumbles 70% On Phase 2 Trial Failure
Article By: Terry Chrisomalis
Friday, July 29, 2016 11:00 AM EST
Seres announced that it had failed to achieve the primary endpoint of a phase 2 clinical trial.
In this article: MCRB
Read
Best IPOs Of 2015
Article By: Zacks Investment Research
Tuesday, December 29, 2015 6:08 AM EST
This past year did not see any record-breaking IPO performances like 2014’s historic market debut of Alibaba Group Holdings Ltd. – it was the largest IPO ever – which raised $25 billion.
In this article: SHAK, MCRB, ACRS, COLL, AVGR
Read
5 New Healthcare IPOs: What Investors Should Know
Article By: Zacks Investment Research
Wednesday, June 24, 2015 8:22 PM EST
All 5 of this week's healthcare IPOs could turn into potential additions into investors’ portfolios; however, several are pre-revenue, and are dependent on research developments. Caution, then, is probably what should be used moving forward.
In this article: RTTR, GKOS, LNTH, CATB, MCRB
Read

PARTNER HEADLINES

Latest Tweets for $MCRB

No tweets yet!